CA-ANDERSEN-GLOBAL
13.7.2024 16:43:35 CEST | Business Wire | Pressemeddelelse
Andersen Global har tilføjet værdiansættelseskapacitet i Afrika og styrket sin overordnede regionale dækning ved at tilknytte to nye samarbejdsvirksomheder – Nelson Thorpe Alonge i Nigeria og Valeo Capital i Sydafrika. Med disse tilføjelser markerer Andersen sine første udbud af værdiansættelsesservice i Afrika og og øger dermed virksomhedens udbud af global værdiansættelse i Nordamerika, Europa, Latinamerika, Mellemøsten og Asien.
Nelson Thorpe Alonge udbyder en komplet portefølje af værdiansættelse af aktiver, der dækker jord og bygninger, anlæg og udstyr, maritime aktiver, olie og gas, luftfart, ejendomsinvesteringer, ejendomsmæglervirksomhed, salg og opkøb, ejendoms- og facilitetsadministration samt rådgivning om ejendomsudstykning. Under ledelse af seniorpartner Victor Alonge betjener virksomheden selskaber, internationale agenturer, diplomatiske enheder, stater, statslige agenturer og personer med stor nettoformue.
"Kundernes succes og tilfredshed står i centrum af vores forretningsstrategi," siger Victor. "Vores samarbejde med Andersen Global er en milepæl for vores virksomhed og viser, at vi altid engagerer os maksimalt i forhold til vores kunder, når vi udvider vores virkeområde til at levere perfekte og omfattende værdiansættelsesløsninger globalt."
Valeo Capital er stiftet af de to partnere Riaan van Heerden og David Tosi og er en specialiseret virksomhed, der arbejder tæt sammen med kunder lige fra greenfieldvirksomheder til børsnoterede selskaber. Virksomheden yder omfattende virksomhedsfinansiering og -rådgivning, herunder fusioner og opkøb, BEE-ejerskabsstrukturering (black economic empowerment), værdiansættelse af virksomheder, due diligence og kapitalrejsning.
"Vi er stolte af den ressourcestyrke, pålidelighed og professionelle indsigt, vi giver til kunder og ønsker at fortsætte med at udvide vores udbud til kunder lokalt og globalt," siger Riaan. "Vores samarbejde med Andersen Global er en yderligere styrkelse af vores teams engagement i at yde klassens bedste service og fastholder vores konkurrencefordel i regionen."
Global Chairman og CEO for Andersen Mark L. Vorsatz siger: "Nelson Thorpe Alonge og Valeo Capital har konsekvent demonstreret deres forpligtelse på god forvaltning og kundeservice, og har skilt sig ud som førende på markedet. Både Nigeria og Sydafrika er som altid vigtige markeder, og virksomhedernes ekspertise er vigtig for vores globale ekspansionsstrategi og for at opfylde de skiftende værdiansættelseskrav fra kunder både regionalt og i udlandet."
Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skattejurister samt skatte- og værdiansættelseseksperter i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 17.000 eksperter i hele verden og en tilstedeværelse på over 475 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240711008688/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
